Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Mefloquine

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total
Phase 1 (1)
Phase 2 (1)
Phase 3 (1)

Trial Status

Completed3

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT00870649Phase 3CompletedPrimary

Efficacy of Bilhvax in Association With Praziquantel for Prevention of Clinical Recurrences of Schistosoma Haematobium

NCT01512277Phase 1Completed

Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis

NCT01132248Phase 2CompletedPrimary

Activity of Mefloquine Against Urinary Schistosomiasis

Showing all 3 trials

Research Network

Common Treatments

  • Mefloquine1
  • Rsh28gst1
  • Bilhvax Vaccine Sh28gst1
  • Sp1

Active Sponsors

  • Institut National de la Santé Et de la Recherche Médicale, France2
  • University Hospital, Lille1
  • Albert Schweitzer Hospital1

Top Investigators

Related Conditions

  • Bilharziasis1
  • Schistosomiasis1
  • Schistosoma Haematobium1

Activity Timeline